Entrar/Registro  
INICIO ENGLISH
 
Gaceta Médica de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Gaceta Médica de México >Año 2006, No. 2


Terán LM, Ledesma-Soto Y, Krengel S, Lezcano-Meza D
Eotaxinas en asma bronquial y poliposis nasal
Gac Med Mex 2006; 142 (2)

Idioma: Español
Referencias bibliográficas: 56
Paginas: 139-144
Archivo PDF: 487.59 Kb.


Texto completo




RESUMEN

Durante la última década se han descubierto tres péptidos con actividad quimotáctica específica para los eosinófilos y que son miembros de la familia de las quimocinas. Estas citocinas inducen a los eosinófilos a realizar diferentes funciones como quimotaxis, migración transendotelial e inducción de la liberación de radicales de oxígeno. Como los eosinófilos infiltran tanto las vías aéreas de pacientes asmáticos como los pólipos nasales, se ha postulado que las eotaxinas pueden ser responsables del reclutamiento de estas células. Los eosinófilos tienen la propiedad de inducir remodelamiento de la matriz extracelular y daño tisular a través de la liberación de proteasas tóxicas, mediadores inflamatorios, citocinas y radicales de oxígeno. Por lo cual, el desarrollo de estrategias terapéuticas que inhiban el reclutamiento de estas células constituye una esperanza en el tratamiento de las enfermedades alérgicas. Este artículo revisa la función de las eotaxinas en asma y poliposis nasal, además de discutir el posible uso de antagonistas de CCR3, receptor de las eotaxinas, como una nueva modalidad terapéutica de asma y poliposis nasal.


Palabras clave: Eotaxina-1, -2 y -3, quimiocinas, CCR3, eosinófilos, asma y pólipos nasales.


REFERENCIAS

  1. Schmid-Grendelmeier P, Altznauer F, Fischer B, Bizer C, StraumannA, Günter M, et al. Eosinophils express functional IL-13 in eosinophilcinflammatory diseases. J Immunol 2002;169:1021-1027.

  2. Stoop AE, van der Heijden HA, Biewenga J, van der Baan S. Eosinophilsin nasal polyps and nasal mucosa: An immonohistochemical study. JAllergy Clin. Immunol 1993;91:616-622.

  3. Tiffany HL, Alkhatib G, Combadiere C, Berger EA, Murphy PM. CCchemokine receptors 1 and 3 are differentially regulated by IL-5 duringmaduration of eosinophilic HL-60 cells. J Immunol 1998;160:1385-1392.

  4. Teran LM. CCL chemokines and asthma. Immunol. Today. 2000;21:235-242.

  5. Barrett JR. Chemokines. Blood 1997;90:909-928.

  6. Jose PJ, Griffiths-Johnson DA, Collins PD, Walsh DT, Moqbel R, et al.Eotaxin: cloning of an eosinophil chemoattractant cytokine and increasedmRNA expresión in allergen-challenged guinea-pig lungs. Biochem BiophysRes Commun 1994;205: 788-794.

  7. Lilly CM, Nacamura H, Kesselman H, Anderson CN, Asano K, GarciaZepeda EA, et al. Expression of eotaxin by human lung epithelial cells. JClin Invest 1997; 99:1767-1773.

  8. Stellato C, Brummet EM, Plitt RJ, Shahabuddin S, Baroody MF, Liu CM,et al. Expression of the C-C chemokine receptor CCR3 in human airwayepithelial cells. J Immunol 2001;166:1457-1461. 9.Clemetson KJ, Clemetson JM, Proudfoot AEI, Power CA, Baggiolini M,Wells TNC. Functional expression of CCR1,CCR3,CCR4, and CXCR4chemokine receptors on human platelets. Blood 2000;96:4046-4054.

  9. Yasmin D, Kluthe C, Buschermöhle T, Barg , Knöb S, Kapp A, et al. IL-13 induces down-regulation of CCR3 protein and mRNA in human eosinophils.J Immunol 2001;167:3443-3453.

  10. Leckie MJ, ten Brinke A , Jamey Khan, Zuzana Diamant, Brian JO’Connor, et al. Effects of an interleukin-5 blocking monoclonal antibodyon eosinophils, airway hyper-responsiveness, and the late asthmaticresponse. Lancet 2000;356:2144-2148.

  11. Palframan RT, Collins PD, Severs NJ, Rothery S, Williams TJ, RankinSM. Mechanisms of acute eosinophil mobilization from the bone marrowstimulated by interleukin 5: the role of specific adhesión molecules andphosphatidylinositol 3-kinase. J Exp Med. 1998;188:1621-1632.

  12. Palframan RT, Collins PD, Williams TJ, Rankin SM. Eotaxin induces arapid release of eosinophils and their progenitors from the bone marrow.Blood 1998;91:2240-2248.

  13. Teran LM, Mochizuki M, Bartels J, Valencia E, Schröder J. Th1 and Th2 typecytokines regulate the expression and production of eotaxin and RANTES byhuman lung fibroblasts. Am J Resp Cell Mol Biol 1999;20:777-786.

  14. Patel VP, Kreider BL, Li Y, Li H, Leung K, Salcedo T, et al. Molecular andfunctional characterization of two novel human C-C chemokines asinhibitors of two distinct classes of myeloid progenitors. J Exp Med 1997;185:1163-1172.

  15. Forssmann U, Uguccioni M, Loetscher P, Dahinden CA, Langen H, ThelenM, et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokinereceptor CCR3, and acts like eotaxin on human eosinophil and basophilleucocytes. J Exp Med 1998;185:2171-2176.

  16. White JR, Imburgia C, Dul E, Appelbaum E, O'Donnell K, O'ShannessyDJ, et al. Cloning and functional characterization of a novel human CCchemokine that binds to the CCR3 receptor and activates human eosinophils.J Leukoc Biol 1997;62:667-675.

  17. Tachimoto H, Burdick MM, Hudson SA, Kikuchi M, Konstantopoulos K,Bochner BS. CCR3 active chemokines promote rapid detachment ofeosinophils from VCAM-1 in vitro. J Immunol 2000;165:2748-2754.

  18. Zimmermann N, Hogan SP, Mishra A, Brandt EB, Bodette TR, Pope SM,et al. Eotaxin-2: A Constitutive Eosinophil Chemokine Induced by AllergenChallenge and IL-4 Overexpression. J Immunol 2000;165:5839-5846.

  19. Shinkai A, Yoshisue H, Koike M, Shoji E, Nakagawa S, Saito A, et al.A novel human CC chemokine, eotaxin-3, which is expressed in IL-4stimulated vascular endothelial cells, exhibits potent activity towardeosinophils. J Immunol 1999;163:1602-1610.

  20. Kitaura M. Molecular cloning of a novel human CC chemokine (eotaxin-3)that is a functional ligand of CC chemokine receptor 3. J Biol Chem 1999;274:27975-27980.

  21. Hoeck J, Woitsetschlager M. STAT6 mediates eotaxin-1 expression in IL-4 or TNF-alpha-induced fibroblasts. J Immunol 2001;166:4507-4515

  22. Teran LM, Carroll M, Frew AJ, Redington AE, Davies DE, Lindley I, etal. Leukocyte recluitment after local endobronchial allergen challenge inasthma. Relationship to procedure and to airway interleukin-8 release. AmJ Respir Crit Care Med 1996;154:469-476.

  23. Frew AJ, St Pierre J, Teran LM, Madden J, Trefillieff A, Carroll MP. Cellularand mediator responses twenty-four hours after local endobronchial allergenchallenge of asthmatic airways. J Allergy Clin Immunol 1996;98:133-143.

  24. Teran LM, Noso N, Carroll MP, Davies DE, Holgate ST, Schröder J.Eosinophil recluitment following allergen challenge is associated with therelease of the chemokine RANTES into asthmatic airways. J Immunol1996;57:1806-1812.

  25. Gonzalo JA, Lloyd CM, Wen D, Albar JP, Wells TN, Proudfoot AEI, et al.The coordinated action of CC chemokines in the lung orchestrates allergicinflammation and airway hyperresponsiveness. J Exp Med 1998;188:157-167.

  26. Hogan SP, Mishra A, Brandt EB, Royalty MP, Pope SM, Zimmermann N,et al. A pathological function for eotaxin and eosinophils in eosinophilicgastrointestinal inflammation. Nature Immunol 2001;1:353-360.

  27. Ying S, Meng Q, Zeibecoglou K, Robinson DS, Macfarlane A, HumbertM, Kay AB. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2,RANTES, monocyte chemoattractant protein-3 (MCP-3), and (MCP-4) andCC chemokine receptor 3 expression in bronchial biopsies from atopic andnonatopic (intrinsic) asthmatic. J Immunol 1999;163:6321-6329.

  28. Lamkhioued B, Renzi PM, Abi-Younes S, Garcia-Zepada EA, AllakhverdiZ, Ghaffar O, et al. Increased expression of eotaxin in bronchoalveolar lavageand airways of asthmatics contributes to the chemotaxis of eosinophils to thesite of inflammation. J Immunol 1997;159:4593-4601.

  29. Nakamura H. Eotaxin and impaired lung function in asthma. Am J Respir CritCare Med 1999;160:1952-1956.

  30. Tateno H, Nakamura H, Minematsu N, Nakajima T, Takahashi S,Nakamura M, et al. Plasma eotaxin level and severity of asthma treatedwith corticosteroid. Respir Med 2004;98:782-90.

  31. Hadjicharalambous C, Dent G, Handy RL, Anderson IK, Davies DE,Djukanovic R. Measurement of eotaxin (CCL11) in induced sputumsupernatants: validation and detection in asthma. J Allergy Clin Immunol2004;Apr;113(4):657-62.

  32. Brown JR, et al. Kinetics of eotaxina expression and its relationship toeosinophil accumulation and activation in bronchial biopsies and bronchoalveolarlavage (BAL) of asthmatic patients after allergen inhalation. Clin Exp Immunol1998;114:137-146.

  33. Teran LM, Carroll MP, Shute JK, Holgate ST. Interleukin 5 release intoasthmatic airways 4 and 24 hours after endobronchial allergen challenge:its relationship with eosinophil recluitment. Cytokine 1999;11:518-522.

  34. Ying S, Robinson DS, Meng Q, Barata LT, McEuen AR, Buckley MG, etal. C-C chemokines in allergen-induced late-phase cutaneous responsesin atopic subjects: association of eotaxin with early 6-hour eosinophils, andof eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hourtissue eosinophilia, and relationship to basophils and other C- C chemokines(mono-cyte chemoattractant protein-3 and RANTES). J Immunol1999;163:3976-398436.Teran LM, González L, Valencia-Maqueda E, Negrete-García C. The kineticsof eotaxin-2 release in nasal secretions following nasal allergen challenge: itsinhibition by a topical steroid. J Allergy Clin Immunol 2003;111: A 520.

  35. Dellacono FR, Eisma R, Lafreniere D, Leonard G, Kreutzer D. Interferongamma expression in human nasal polyps. Laryngoscope 1997;107:626-630.

  36. Azuara-Pliego E, García-Palmer R. Rinología ciencia y arte.1996. MéxicoD.F. Editorial JGH. pp. 148-149.

  37. Pawankar R. Nasal polyposis: an update: editorial review. Curr Opin AllergyClin Immunol 2003;3(1):1-6.

  38. Teran LM, Park HS, Djukanovic R, Roberts K, Holgate ST. Culture nasalpolyps from nonatopic and atopic patients release RANTES spontaneouslyand after stimulation with phytohemagglutinin. J Allergy Clin Immunol1997;100:499-504.

  39. Bartels J, Maune S, Meyer JE, Kulke R, Schluter C, Rowert J, et al. In-creased eotaxina mRNA expression in non-atopic and atopic nasal polyps:comparison to RANTES and MCP-3 expression. Rhinology 1997;35(4):171-174.

  40. Bacher C, Gevaert P, Holtappels G, Johansson SG, van CauwenbergeP. Total and specific IgE in nasal polyps is related to local eosinophilicinflammation. J Allergy Clin Immunol. 2001;107(4):607-614.

  41. Lamblin C, Bolard F, Gosset P, Tsicopoulos A, Perez Darras JJ, et al.Bronchial interleukin-5 and eotaxina expression in nasal polyposis. Am JRespir Crit Care Med 2001;163:1226-1232.

  42. Woodworth BA, Joseph K, Kaplan AP, Schlosser RJ. Alterations in eotaxin,monocyte chemoattractant protein-4, interleukin-5, and interleukin-13 aftersystemic steroid treatment for nasal polyps. Otolaryngol Head Neck Surg2004;13:585.

  43. Seto H, Suzaki H, Shioda S. Immunohistochemical localization of eotaxinimmunoreactivity in nasal polyps. Acta Otolaryngol Suppl 2004;553:99-104.

  44. Jahnsen FL, Haye R, Gran E, Brandtzaeg P, Johansen FE.Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, andmonocyte-chemotactic protein-4 in human airway inflammation with eosinophilia.J Immunol 1999;163(3):1545-1551.

  45. Lezcano-Meza D, Dávila-Dávila B, Vega-Miranda A, Negrete-García MC,Teran. LM. Interleukin(IL)-4 and to a Lesser Extent either IL-13 or Interferon(IFN)-gamma Regulate the Production of Eotaxin-2/CCL24 in Nasal Polyps.Allergy 2003;58:1011-1017.

  46. Fujisawa T. Chemokines induce eosinophil degranulation through CCR3.J Allergy Clin Immunol 2000;106:507-513.

  47. Heath H, Qin S, Rao P, Wu L, LaRosa G, Kassam N, et al. Chemokinereceptor usage by human eosinophils. The importance of CCR3 demonstrateusing an antagonistic monoclonal antibody. J Clin Invest 1997;99:178-184.

  48. Zimmermann N, Daugherty BL, Stark JM, Rothenberg ME. Molecular analysisof CCR-3 events in eosinophilic cell. J Immunol 2000;164:1055-1064.

  49. Elsner J, Petering H, Hochstetter R, Kimmig D, Wells TN, Kapp A,Proudfoot AE. The CC chemokines antagonist Met-RANTES inhibitseosinophil effector functions through the chemokine receptors CCR1 andCCR3. Eur J Immunol 1997;27:2892-2898.

  50. Sabroe I, Peck MJ, Van Keulen BJ, Jorritsma A, Simmons G, ClaphamPR, et al. A small molecule antagonist of chemokine receptors CCR1 andCCR3. Potent inhibition of eosinophil function and CCR3 mediated HIV-1entry. J Biol Chem 2000;275:25985-25992.

  51. Loetscher P, Pellegrino A, Gong JH, Mattioli I, Loetscher M, Bardi G,et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig and IP-10 arenatural antagonists for CCR3. J Biol Chem 2001;276:2986-2991.

  52. Grzegorzewski KJ, Yao XT, Kreider B, Olsen HS, Morris TS, Zhang L,et al. Analysis of eosinophils and myeloid progenitor responses to modifiedforms of mipf-2. Cytokine. 2001;13:209-219.

  53. Teixeira MM, Wells TN, Lukacs NW, Proudfoot AE, Kunkel SL, WilliamsTJ, Hellewell PG. Chemokine-induced eosinophil recruitment. Evidence ofa role for endogenous eotaxin in an in vivo allergy model in mouse skin. JClin Invest 1997;100(7):1657-66.

  54. Berkman MP, Finkelman FD, Rothenberg ME. Murine Eotaxin-2: aconstitutive eosinophil chemokine induced by allergen challenge and IL-4 overexpression. J Immunol 2000;165:5839-5846.



>Revistas >Gaceta Médica de México >Año2006, No. 2
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019